< Back to Press Releases

Monthly Archives: November 2014

‘Utter neglect’ of rheumatic heart disease revealed by results from global study

Rheumatic heart disease (RHD) – the most common acquired heart disease in children in many countries of the world – is being neglected and poorly treated, according to new findings from the Global Rheumatic Heart Disease Registry (the REMEDY study), … Continue reading

Published Wednesday, November 26th, 2014 at 12:05 am
Posted in Cardiology

Early results of new drug, ASP8273, show response in Japanese patients with treatment-resistant non-small cell lung cancer

Barcelona, Spain: In a second presentation looking at new ways of treating non-small cell lung cancer (NSCLC) that has both the EGFR and T790M mutations, researchers told the 26th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, … Continue reading

Published Friday, November 21st, 2014 at 12:01 am
Posted in Cancer, Genetics

Three drugs may be better than one for certain patients with advanced colorectal cancer

Barcelona, Spain: Patients with a form of advanced colorectal cancer that is driven by a mutated version of the BRAF gene have limited treatment options available. However, results from a multi-centre clinical trial suggest that the cancer may respond to … Continue reading

Published Thursday, November 20th, 2014 at 1:17 pm
Posted in Cancer, Genetics

Early results show response to new drug in patients with lymphomas and advanced solid tumours

Barcelona, Spain: Patients with B-cell Non-Hodgkin lymphomas and advanced solid tumours have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial. Preliminary results from the trial were presented … Continue reading

Published Thursday, November 20th, 2014 at 12:01 am
Posted in Cancer

Researchers pioneer new approach to treating HPV-related cervical cancer

Barcelona, Spain: A drug that is already well established as a treatment for infection of the retina in people with AIDS has been shown, for the first time, to sensitise cervical cancer to chemotherapy and radiotherapy without an increase in … Continue reading

Published Thursday, November 20th, 2014 at 12:01 am
Posted in Cancer

Researchers identify biological indicator of response to new ovarian cancer drug

Barcelona, Spain: Researchers have found a way of identifying which ovarian cancer patients are likely to respond well to a new anti-cancer drug called rucaparib. Results of clinical trials have shown that women with tumours that are sensitive to platinum-based … Continue reading

Published Thursday, November 20th, 2014 at 12:01 am
Posted in Cancer, Genetics

Trial results show treatment-resistant advanced non-small cell lung cancer responds to new drug, rociletinib

Barcelona, Spain: A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in … Continue reading

Published Wednesday, November 19th, 2014 at 12:05 am
Posted in Cancer, Genetics

Patients with advanced papillary kidney cancer respond well to a combination of two existing anti-cancer drugs

Barcelona, Spain: Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs. Dr Ramaprasad Srinivasan, head … Continue reading

Published Wednesday, November 19th, 2014 at 12:01 am
Posted in Cancer

Galeterone shows activity in a variant form of castration-resistant prostate cancer

Barcelona, Spain: Results from a trial of the anti-cancer drug galeterone show that it is successful in lowering prostate-specific antigen (PSA) levels in men with a form of prostate cancer that is resistant to treatment with hormone therapy (castration-resistant prostate … Continue reading

Published Wednesday, November 19th, 2014 at 12:01 am
Posted in Cancer

First demonstration of anti-cancer activity for AG-120, an inhibitor of the IDH1 mutation, in patients with advanced leukaemia

Barcelona, Spain: A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced … Continue reading

Published Wednesday, November 19th, 2014 at 12:01 am
Posted in Cancer
.